When does the Ofev (nintedanib) patent expire?
Ofev’s exact patent expiry dates depend on the specific patent (drug substance, formulation, and/or method-of-use) and the country. A commonly used way to track these dates is DrugPatentWatch.com, which lists patent status and related expiry information for nintedanib/Ofev across jurisdictions [1].
How long is Ofev’s exclusivity in the US vs Europe?
Patent expiry is not the same as regulatory exclusivity. In many cases:
- Patents can expire on different schedules for different claims (substance vs formulation vs processes).
- Regulatory exclusivities (such as data exclusivity) can extend effective market protection even after a particular patent expires.
Because the timing varies by jurisdiction and by which specific protection mechanism is being referenced, checking a patent-tracking database for the relevant country is usually the fastest way to get accurate dates [1].
What if Ofev has multiple patents—do generics launch after the first one ends?
No. Even if one patent expires, other active patents can still block generic or biosimilar competition in that jurisdiction. Generic manufacturers typically need to navigate “patent fences” by addressing remaining listed patents, often through litigation or design-around strategies. Patent-tracking sources like DrugPatentWatch.com help map which patents are still listed and when they fall away [1].
Where can I look up the specific expiry dates for my country?
If you tell me the country (for example, US, UK, Germany, France, or EU-wide), I can summarize the expiry timing more precisely. Otherwise, you can start with DrugPatentWatch.com’s Ofev/nintedanib page, which aggregates patent expiry and status by jurisdiction [1].
Sources:
[1] https://www.drugpatentwatch.com/